PTCT PTC Therapeutics Inc.

15.78
+0.05  (0%)
Previous Close 15.73
Open 15.68
Price To book 4.48
Market Cap 654705572
Shares 41,489,580
Volume 361,816
Short Ratio 6.04
Av. Daily Volume 1,405,590

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171173019
  2. 8-K - Current report 171172283
  3. 8-K - Current report 171152542
  4. 8-K - Current report 171108342
  5. 8-K - Current report 171090480

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial initiated October 2016. Phase 3 part of trial has commenced - noted October 12, 2017.
RG7916
Spinal Muscular Atrophy (SMA)
Received a Refusal to File letter for their NDA Filing - February 23 2016. Appeal rejected October 17, 2016. Decision made to resubmit NDA during 1Q 2017 under protest. New PDUFA date October 24, 2017. Advisory Committee Meeting September 28, 2017 voted that although it is possible that ataluren may be effective, the data are inconclusive, and more work would be needed to establish whether ataluren is effective. FDA issued CRL October 25, 2017.
Ataluren
Duchenne muscular dystrophy caused by nonsense mutations (nmDMD)
Phase 3 data released March 2, 2017 - endpoints not met. Development to be discontinued.
Translarna
Nonsense mutation cystic fibrosis

Latest News

  1. PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  2. New Research: Key Drivers of Growth for Masco, Dextera Surgical, PTC Therapeutics, American International Group, Wyndham Worldwide, and Hecla Mining - A Look Behind the Scenes at Consolidated Results, Factors of Influence, Major Initiatives and Sustained Production
  3. ETFs with exposure to PTC Therapeutics, Inc. : November 8, 2017
  4. PTC Therapeutics, Inc. :PTCT-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017
  5. Edited Transcript of PTCT earnings conference call or presentation 2-Nov-17 8:30pm GMT
  6. PTC Therapeutics reports 3Q loss
  7. PTC Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update
  8. PTC Therapeutics, Inc. to Host Earnings Call
  9. Today's Research Reports on Trending Tickers: Keryx Biopharmaceuticals and PTC Therapeutics
  10. ETFs with exposure to PTC Therapeutics, Inc. : October 26, 2017
  11. FDA declines to approve PTC's Duchenne drug
  12. PTC Therapeutics Receives Complete Response Letter for Ataluren's NDA
  13. PTC Therapeutics to Present at the Credit Suisse 26th Annual Healthcare Conference
  14. PTC THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of PTC Therapeutics, Inc. - (PTCT)
  15. PTC Therapeutics to Host Conference Call to Discuss Third Quarter Financial Results
  16. PTC Therapeutics, Sunfish Milestone Payment, Analysts Opinion, and October PDUFA Date
  17. PTC THERAPEUTICS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of PTC Therapeutics, Inc. - (PTCT)
  18. Spinal Muscular Atrophy Program Advances into Pivotal Study in SMA Patients
  19. Is The Likelihood Of An FDA Complete Response Letter Fully Priced In To PTC Therapeutics?

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171173019
  2. 8-K - Current report 171172283
  3. 8-K - Current report 171152542
  4. 8-K - Current report 171108342
  5. 8-K - Current report 171090480
  6. CT ORDER - Confidential treatment order 171059531
  7. S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers 171049607
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 171016534
  9. 8-K - Current report 171015232
  10. 8-K/A [Amend] - Current report 17945567